538965 — CONCORD DRUGS Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapMomentum Trap

Annual income statement for CONCORD DRUGS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	514	590	521	449	452
Cost of Revenue
Gross Profit	91.8	169	111	117	100
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	457	551	491	424	425
Operating Profit	56.2	38.3	29.5	24.9	27
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	42.9	22.5	12.5	6.29	6.91
Provision for Income Taxes
Net Income After Taxes	32.8	15.9	9.86	4.72	3.36
Net Income Before Extraordinary Items
Net Income	32.8	15.9	9.86	4.72	3.36
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	32.8	15.9	9.86	4.72	3.36
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.462	1.82	1.06	0.472	0.34